Status:

TERMINATED

Multidimensional Assessment of Dyspnea in Asthma

Lead Sponsor:

University Hospital, Lille

Conditions:

Asthma

Eligibility:

All Genders

18+ years

Brief Summary

Breathlessness is a symptom of asthma that occurs in relation with lower airway obstruction. However, this sensation is not specific of asthma and may be the expression of other disorders. In particul...

Eligibility Criteria

Inclusion

  • Diagnosis of asthma confirmed by:
  • A history of symptoms compatible with asthma
  • AND a history of airway obstruction, according to the GINA definition (2017): FEV1/FVC ratio lower than the lower limit of the predicted value at baseline or after a bronchial provocation test
  • AND a variability of airway obstruction defined by at least one of the following criteria:
  • oReversibility of airway obstruction after bronchodilators (400 µg of salbutamol): FEV 1 increases by\> 200 mL and\> 12% compared to baseline
  • OR delta peak-flow over the day / average peak-flow averaged over 2 weeks\> 10%
  • OR variability in FEV1 between two visits\> 200 mL and\> 12%
  • OR an increase in FEV1 of\> 200 mL and\> 12% compared to the baseline after 4 weeks of treatment with oral corticosteroids
  • OR a positive methacholine challenge: decrease in FEV1 by more than 20% for a dose \<1600 µg
  • Experience of dyspnea in the past 7 days
  • Age\> 18 years old
  • Social protection affiliation 5. Written informed consent

Exclusion

  • Age \<18 years old
  • Active smoker or quitting smoking for less than a year
  • Severe exacerbation or respiratory infection within 4 weeks before inclusion (severe exacerbation is defined by an increase in systemic corticosteroid therapy for at least 3 days or injection of a single dose of delayed corticosteroid, emergency room visit due to asthma (with systemic corticosteroid therapy), or hospitalization due to asthma).
  • Inability to respond to questionnaires for any reason
  • Presence of any pathology other than asthma which may be responsible for dyspnea, in particular cardiovascular or respiratory (ischemic heart disease, heart failure, chronic obstructive pulmonary disease, diffuse interstitial pneumonitis, lung cancer, non-exhaustive list) with the exception of anxiety and hyperventilation syndrome
  • Pregnancy
  • Persons under guardianship
  • Refusal to sign consent or participate in the study
  • No social protection affiliation

Key Trial Info

Start Date :

May 18 2020

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

August 11 2022

Estimated Enrollment :

133 Patients enrolled

Trial Details

Trial ID

NCT04286906

Start Date

May 18 2020

End Date

August 11 2022

Last Update

January 26 2023

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Ch Dunkerque

Dunkirk, France

2

Hopital Saint Vincent - Saint Antoine - Lille

Lille, France, 59037

3

Hop Calmette Chu Lille

Lille, France

4

Hu Paris Nord Site Bichat Aphp - Paris 18

Paris, France